SG10201704008RA - Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction - Google Patents

Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Info

Publication number
SG10201704008RA
SG10201704008RA SG10201704008RA SG10201704008RA SG10201704008RA SG 10201704008R A SG10201704008R A SG 10201704008RA SG 10201704008R A SG10201704008R A SG 10201704008RA SG 10201704008R A SG10201704008R A SG 10201704008RA SG 10201704008R A SG10201704008R A SG 10201704008RA
Authority
SG
Singapore
Prior art keywords
regulatory elements
fetal hemoglobin
distal regulatory
targeting bcl11a
reinduction
Prior art date
Application number
SG10201704008RA
Other languages
English (en)
Inventor
H Orkin Stuart
E Bauer Daniel
Xu Jian
Original Assignee
The Children's Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corp filed Critical The Children's Medical Center Corp
Publication of SG10201704008RA publication Critical patent/SG10201704008RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201704008RA 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction SG10201704008RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261730323P 2012-11-27 2012-11-27
US201261730369P 2012-11-27 2012-11-27
US201361776144P 2013-03-11 2013-03-11
US201361889174P 2013-10-10 2013-10-10

Publications (1)

Publication Number Publication Date
SG10201704008RA true SG10201704008RA (en) 2017-06-29

Family

ID=50828461

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201704008RA SG10201704008RA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
SG11201504038XA SG11201504038XA (en) 2012-11-27 2013-11-27 Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
SG10202110062SA SG10202110062SA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11201504038XA SG11201504038XA (en) 2012-11-27 2013-11-27 Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction
SG10202110062SA SG10202110062SA (en) 2012-11-27 2013-11-27 Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction

Country Status (18)

Country Link
US (4) US9822355B2 (he)
EP (2) EP2925864B1 (he)
JP (2) JP6542124B2 (he)
KR (1) KR102240555B1 (he)
CN (2) CN109554350B (he)
AU (3) AU2013352156B2 (he)
BR (1) BR112015011995B1 (he)
CA (1) CA2892860C (he)
DK (2) DK3502240T3 (he)
ES (2) ES2884925T3 (he)
HK (1) HK1215720A1 (he)
IL (1) IL238949B (he)
MX (1) MX361412B (he)
PT (2) PT3502240T (he)
SA (1) SA515360489B1 (he)
SG (3) SG10201704008RA (he)
WO (1) WO2014085593A1 (he)
ZA (1) ZA201504004B (he)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
SG10201704008RA (en) 2012-11-27 2017-06-29 The Children's Medical Center Corp Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
JP6535333B2 (ja) * 2013-09-04 2019-06-26 シーエスアイアール 遺伝子発現をサイレンシングする遺伝子制御エレメントを標的とする部位特異的ヌクレアーゼ単一細胞アッセイ
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
PT3068881T (pt) * 2013-11-13 2019-05-31 Childrens Medical Center Regulação da expressão de genes mediada por nucleases
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CA2946309C (en) 2014-04-25 2021-11-09 Michael MILSOM Synthetic bcl11a micrornas for treating hemoglobinopathies
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
IL234638A0 (he) 2014-09-14 2014-12-02 Yeda Res & Dev אנטגוניסטים לקולטני nmda לטיפול במחלת גושה
EP3262173A2 (en) 2015-02-23 2018-01-03 Crispr Therapeutics AG Materials and methods for treatment of human genetic diseases including hemoglobinopathies
BR112017017812A2 (pt) 2015-02-23 2018-04-10 Crispr Therapeutics Ag materiais e métodos para tratamento de hemoglobinopatias
EP4218771A1 (en) 2015-03-27 2023-08-02 Yeda Research and Development Co. Ltd Methods of treating motor neuron diseases
WO2016182917A1 (en) * 2015-05-08 2016-11-17 Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016183298A2 (en) * 2015-05-12 2016-11-17 Sangamo Biosciences, Inc. Nuclease-mediated regulation of gene expression
MY189601A (en) * 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps
CN108026526B (zh) 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
IL258821B (he) 2015-10-23 2022-07-01 Harvard College עורכי נוקליאובסיס ושימושים שלהם
WO2017077394A2 (en) 2015-11-04 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US20190010495A1 (en) * 2015-12-28 2019-01-10 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
JP2019505511A (ja) 2016-01-06 2019-02-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法
CN109068605B (zh) 2016-01-21 2022-11-11 以色列国家农业和农村发展农业研究组织沃尔坎尼中心 单性结实植物及其产生方法
US11261433B2 (en) 2016-01-31 2022-03-01 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
CA3014078A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
US20190046497A1 (en) 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
KR102532663B1 (ko) * 2016-03-14 2023-05-16 에디타스 메디신, 인코포레이티드 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물
FI3445388T3 (fi) * 2016-04-18 2024-05-15 Vertex Pharma Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
IL247368A0 (he) 2016-08-18 2016-11-30 Yeda Res & Dev שימושים אבחנתיים וטיפוליים באקסוזומים
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
WO2018096547A1 (en) 2016-11-28 2018-05-31 Yeda Research And Development Co. Ltd. Isolated polynucleotides and polypeptides and methods of using same for expressing an expression product of interest
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US20200124615A1 (en) 2016-12-29 2020-04-23 Ukko Inc. Methods for identifying and de-epitoping allergenic polypeptides
IL250479A0 (he) 2017-02-06 2017-03-30 Sorek Rotem תאים מהונדסים גנטית המבטאים מערכת disarm המקנה עמידות לפאג'ים ושיטות לייצור שלהם
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
IL252151A0 (he) 2017-05-07 2017-07-31 Fainzilber Michael טיפול בהפרעות דחק
WO2018209158A2 (en) * 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
IL253642A0 (he) 2017-07-24 2017-09-28 Seger Rony טיפול משולב לטיפול בסרטן
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
WO2019038771A1 (en) 2017-08-23 2019-02-28 Technion Research & Development Foundation Limited COMPOSITIONS AND METHODS FOR ENHANCING ALCOHOL TOLERANCE IN YEAST
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CN109722414A (zh) * 2017-10-27 2019-05-07 博雅辑因(北京)生物科技有限公司 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
IL255664A0 (he) 2017-11-14 2017-12-31 Shachar Idit תאי גזע המטופויטיים עם תכונות משופרות
WO2019147302A1 (en) * 2018-01-26 2019-08-01 Bauer Daniel E Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
IL257225A (he) 2018-01-29 2018-04-09 Yeda Res & Dev טיפול לסרקומה
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3818075A1 (en) 2018-07-04 2021-05-12 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
IL262658A (he) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center מניעת התפתחות המטואפיזיס קלונלי תלוי גיל ומחלות הקשורות בו
EP3887514A4 (en) * 2018-11-30 2024-01-17 Childrens Medical Ct Corp THERAPEUTIC GENERATE EDITING FOR ELAN-ASSOCIATED DISEASE
CN109486850B (zh) * 2018-12-04 2021-05-25 厦门大学 Uv-b光下调控染色质长距离相互作用的光遗传学工具
CA3128360A1 (en) 2019-03-05 2020-09-10 Yuval CINNAMON Genome-edited birds
WO2020191153A2 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN111939271A (zh) * 2019-04-30 2020-11-17 博雅辑因(北京)生物科技有限公司 一种血红蛋白病治疗有效性预测方法
US20220193142A1 (en) * 2019-04-30 2022-06-23 Edigene Inc. Method for predicting effectiveness of treatment of hemoglobinopathy
US20220251148A1 (en) 2019-07-04 2022-08-11 Ukko Inc. De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity
IL268111A (he) 2019-07-16 2021-01-31 Fainzilber Michael שיטות לטיפול בכאב
IL270306A (he) 2019-10-30 2021-05-31 Yeda Res & Dev מניעה וטיפול של ממאירויות מיאלואידיות ופרה–מיאלואידיות
IL271656A (he) 2019-12-22 2021-06-30 Yeda Res & Dev מערכת ושיטות לזיהוי תאים שעברו עריכה של הגנום
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
KR20230019843A (ko) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
CN111705044B (zh) * 2020-05-23 2022-12-27 南京大学 新型可控高活性g四链体dna酶的构建
JP2023545999A (ja) 2020-10-05 2023-11-01 プロタリクス リミテッド ダイサー(dicer)様ノックアウト植物細胞
EP4228637A1 (en) 2020-10-15 2023-08-23 Yeda Research and Development Co. Ltd Method of treating myeloid malignancies
EP4251641A1 (en) 2020-11-26 2023-10-04 Ukko Inc. Modified high molecular weight glutenin subunit and uses thereof
IL279559A (he) 2020-12-17 2022-07-01 Yeda Res & Dev בקרת תהליך היוביקוויטינציה של mlkl לטיפול במחלה
CA3202382A1 (en) 2020-12-18 2022-06-23 Yeda Research And Development Co. Ltd. Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same
BR112023023486A2 (pt) 2021-05-10 2024-01-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Composição farmacêutica, e, método de tratamento de uma doença ou condição na qual um efeito clínico benéfico é obtido pela redução na atividade de sintase de óxido nítrico neuronal
WO2022240787A1 (en) * 2021-05-13 2022-11-17 The Children's Medical Center Corporation Methods for stratifying subjects for fetal hemoglobin reinduction
CN117836402A (zh) 2021-06-13 2024-04-05 耶路撒冷希伯来大学伊森姆研究发展有限公司 重编程人细胞的方法
CA3226947A1 (en) 2021-08-03 2023-02-09 Muhammad YASSIN Engineered tcr complex and methods of using same
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
CA3234612A1 (en) 2021-10-14 2023-04-20 Weedout Ltd. Methods of weed control
WO2023240282A1 (en) 2022-06-10 2023-12-14 Umoja Biopharma, Inc. Engineered stem cells and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5731156A (en) * 1996-10-21 1998-03-24 Applied Imaging, Inc. Use of anti-embryonic hemoglobin antibodies to identify fetal cells
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2215494T5 (es) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Moléculas de RNA pequeñas que median la interferencia de RNA
EP1560931B1 (en) 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
DE60333487D1 (de) 2002-12-13 2010-09-02 Genetix Pharmaceuticals Inc Therapeutische retrovirus-vektoren für gentherapie
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
WO2007047859A2 (en) 2005-10-18 2007-04-26 Precision Biosciences Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US20080051431A1 (en) 2006-05-26 2008-02-28 Dominique Verhelle Methods and compositions using immunomodulatory compounds in combination therapy
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
GB0713183D0 (en) 2007-07-06 2007-08-15 King S College London Method
DK2334794T3 (en) 2008-09-15 2017-02-20 Children's Medical Center Corp MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
US20110294114A1 (en) 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
MA33899B1 (fr) 2009-12-08 2013-01-02 Hemaquest Pharmaceuticals Inc Procedes et regimes a faible dose pour des troubles des globules rouges
JP2011135864A (ja) * 2009-12-30 2011-07-14 Korea Univ Research & Business Foundation Oct4及びBmi1、またはその上位調節子を用いて体細胞から胚幹細胞類似細胞への逆分化を誘導する組成物及びこれを用いた胚幹細胞類似細胞の製造方法
HUE040278T2 (hu) 2010-04-23 2019-02-28 Cold Spring Harbor Laboratory Új szerkezetileg tervezett shRNS-ek
WO2012073047A2 (en) 2010-12-03 2012-06-07 Genome Research Limited Compositions and methods
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
KR20150029756A (ko) 2011-06-10 2015-03-18 블루버드 바이오, 인코포레이티드. 부신백질이영양증 및 부신척수신경병증을 위한 유전자 요법 벡터
SG10201602423TA (en) 2011-09-30 2016-05-30 Bluebird Bio Inc Compounds For Improved Viral Transduction
ES2641840T3 (es) 2012-02-24 2017-11-14 Fred Hutchinson Cancer Research Center Composiciones y métodos para el tratamiento de hemoglobinopatías
AP2014008100A0 (en) 2012-05-16 2014-12-31 Gen Hospital Corp Compositions and methods for modulating hemoglobingene family expression
PE20150336A1 (es) 2012-05-25 2015-03-25 Univ California Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
SG10201704008RA (en) * 2012-11-27 2017-06-29 The Children's Medical Center Corp Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
ES2553782T3 (es) 2012-12-12 2015-12-11 The Broad Institute, Inc. Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
WO2014093965A1 (en) 2012-12-14 2014-06-19 Case Western Reserve University Genomic rna packaging enhancer element
CN116083487A (zh) 2013-05-15 2023-05-09 桑格摩生物治疗股份有限公司 用于治疗遗传病状的方法和组合物
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
PT3068881T (pt) 2013-11-13 2019-05-31 Childrens Medical Center Regulação da expressão de genes mediada por nucleases
CN104955119B (zh) 2014-03-26 2019-11-26 南京中兴新软件有限责任公司 一种基于流量的网络切换方法、装置和终端
EP3134434A4 (en) 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
CA2946309C (en) 2014-04-25 2021-11-09 Michael MILSOM Synthetic bcl11a micrornas for treating hemoglobinopathies
EP3998278A1 (en) 2014-04-25 2022-05-18 2seventy bio, Inc. Mnd promoter chimeric antigen receptors
WO2015183667A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
BR112017012502B1 (pt) 2014-12-12 2020-09-15 Bluebird Bio, Inc. Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
EP3294879A4 (en) 2015-05-14 2019-02-20 University of Southern California OPTIMIZED GENETIZATION WITH A RECOMBINANT ENDONUCLEASE SYSTEM
AU2016315704B2 (en) 2015-08-31 2022-08-11 Helixmith Co., Ltd Anti-sialyl Tn chimeric antigen receptors
GB201522243D0 (en) 2015-12-16 2016-01-27 Ucl Business Plc Treatment
CA3014078A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery

Also Published As

Publication number Publication date
EP2925864A1 (en) 2015-10-07
US10472619B2 (en) 2019-11-12
SA515360489B1 (ar) 2016-12-25
PT2925864T (pt) 2019-02-06
AU2013352156A1 (en) 2015-06-11
AU2013352156B2 (en) 2018-12-06
JP2015536657A (ja) 2015-12-24
CN109554350B (zh) 2022-09-23
CN104955943A (zh) 2015-09-30
AU2018278850A1 (en) 2019-01-17
US20180119130A1 (en) 2018-05-03
AU2018278850B2 (en) 2021-05-27
AU2021218012A1 (en) 2021-09-09
EP3502240A1 (en) 2019-06-26
SG11201504038XA (en) 2015-06-29
MX361412B (es) 2018-12-05
US20150307867A1 (en) 2015-10-29
HK1215720A1 (zh) 2016-09-09
EP3502240B1 (en) 2021-05-05
MX2015006528A (es) 2016-07-13
EP2925864A4 (en) 2016-07-13
PT3502240T (pt) 2021-08-11
ZA201504004B (en) 2016-11-30
ES2708948T3 (es) 2019-04-12
US20200087651A1 (en) 2020-03-19
ES2884925T3 (es) 2021-12-13
US20230348887A1 (en) 2023-11-02
CA2892860A1 (en) 2014-06-05
US11542493B2 (en) 2023-01-03
EP2925864B1 (en) 2018-10-31
CA2892860C (en) 2023-01-03
DK2925864T3 (en) 2019-02-11
WO2014085593A1 (en) 2014-06-05
AU2021218012B2 (en) 2023-06-29
SG10202110062SA (en) 2021-11-29
KR102240555B1 (ko) 2021-04-16
US9822355B2 (en) 2017-11-21
IL238949A0 (he) 2015-07-30
JP6633602B2 (ja) 2020-01-22
BR112015011995B1 (pt) 2023-02-07
JP2018085987A (ja) 2018-06-07
CN109554350A (zh) 2019-04-02
JP6542124B2 (ja) 2019-07-10
CN104955943B (zh) 2018-09-25
IL238949B (he) 2019-06-30
DK3502240T3 (da) 2021-08-09
KR20150107726A (ko) 2015-09-23
BR112015011995A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
HK1215720A1 (zh) 用於胎兒血紅蛋白再誘導的靶向 遠端調控元件
EP2916905A4 (en) MEDICAL CONNECTION
EP2842540A4 (en) MEDICAL CONNECTOR
EP2837341A4 (en) MEDICAL MANIPULATOR
EP2837354A4 (en) MEDICAL HANDLING DEVICE
ZA201300386B (en) Connector for medical lines
EP2837340A4 (en) MEDICAL MANIPULATOR
EP2812777A4 (en) STRING COMPLETION
GB201218307D0 (en) Patient monitor
EP2815691A4 (en) ENDOSCOPE
PL2882487T3 (pl) Złączka do zastosowań medycznych
EP2939632A4 (en) SURGICAL ROBOT
EP2891448A4 (en) ENDOSCOPE
EP2820999A4 (en) ENDOSCOPE
EP2692278A4 (en) Borescope
EP2837320A4 (en) Borescope
EP2805664A4 (en) Borescope
EP2656779A4 (en) ENDOSCOPE
EP2868252A4 (en) Borescope
EP2835093A4 (en) ENDOSCOPE
HK1211480A1 (en) External preparation for skin
EP2881048A4 (en) MEDICAL MANIPULATOR
EP2799000A4 (en) ENDOSCOPE
EP2735260A4 (en) ENDOSCOPE
EP2856924A4 (en) Borescope